M.A. Wright, M. Guasp, and C. Lachner have no disclosures; G.S. Day has no competing interests that are directly relevant to this work, his research is supported by NIH (K23AG064029, U01AG057195, U01NS120901, U19AG032438) and the Chan Zuckerberg Initiative, he serves as a consultant for Parabon Nanolabs Inc. and as a Topic Editor (Dementia) for DynaMed (EBSCO) , he is the co -Project PI for a clinical trial in anti-NMDAR encephalitis, which receives support from Horizon Pharmaceuticals, he has developed educational materials for PeerView Media, Inc., and Continuing Education Inc., he owns stock in ANI pharmaceuticals, his institution has received support from Eli Lilly for development and participation in an educational event promoting early diagnosis of symptomatic Alzheimer's disease, and in -kind contributions of radiotracer precursors for tau -PET neuroimaging in studies of mem- ory and aging (via Avid Radiopharmaceuticals, a wholly -owned sub- sidiary of Eli Lilly) ; G. Gombolay receives part time salary support from the Centers for Disease Control and Prevention for acute flaccid myelitis surveillance and an honorarium as Media Editor for Pediatric Neurology, and is funded by the National Center for Advancing Trans- lational Sciences of the National Institutes of Health under Award Number UL1TR002378 and KL2TR002381; M.J. Titulaer has received research funds for serving on a scientific advisory board of Horizon Therapeutics, for consultation at Guidepoint Global LLC, for consulta- tion at UCB, and publication royalties for UpToDate, he has received an unrestricted research grant from CSL Behring, he was funded by the Dutch EpilepsieNL Foundation (NEF 19-08) , an Interlaken Leadership award, Dioraphte (2001 0403) , the Dutch Research Council (ZonMW, PARAD E -VIMP) and E -RARE JTC 2018 (UltraAIE, 90030376505) ; S.L. Clardy is a site investigator for the Alexion clinical trial for Eculizumab in Relapsing NMO patients, now in long-term follow-up, and the UCB clinical trial for relapsing MOGAD patients (cosMOG) , currently actively enrolling, she has received research support from NIH/NINDS (U01, The ExTINGUISH Trial) , the Western Institute for Veteran Research, the Siegel Rare Neuroimmune Association, the Immune Deficiency Foun- dation, Viela Bio/Horizon, Alexion/AstraZeneca, the Barbara Gural Steinmetz Foundation, Sumaira Foundation for NMO, she has served on consulting/Scientific Advisory Boards for Alexion, VielaBio/Horizon, Genentech/Roche, she is on the medical Advisory Board of the Sumaira Foundation for NMO (unpaid) , she is also the Section Editor of Neurology Podcast and Neurology Minute and on the Editorial Board for Neurology: Neuroimmunology and Neuroinflammation.